This Article Abstract Full Text Full Text (PDF) Correction (v45,p811) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (39) Citing Articles via Google Scholar Google Scholar Articles by Shlipak, M. G. Articles by Stehman-Breen, C. Search for Related Content PubMed PubMed Citation Articles by Shlipak, M. G. Articles by Stehman-Breen, C.

Cystatin-C and mortality in elderly persons with heart failure

Michael G. Shlipak, MD, MPH^*,*, Mark J. Sarnak, MD, Ronit Katz, PhD, Linda Fried, MD, MPH, Stephen Seliger, MD^||, Anne Newman, MD, MPH^¶, David Siscovick, MD, MPH^# and Catherine Stehman-Breen, MD, MS^**

^* General Internal Medicine Section, Veterans Affairs Medical Center, and Departments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, California
Division of Nephrology, Department of Medicine, Tufts-New England Medical Center, Boston, Massachusetts
Collaborative Health Studies Coordinating Center, Seattle, Washington
Renal Section, Medical Service, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
^|| Nephrology Division, University of Washington School of Medicine, Seattle, Washington
^¶ Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, and Division of Geriatric Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
^# Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington
^** Amgen Inc., Thousand Oaks, California

View larger version (22K): [in a new window]   Figure 1 Association of cystatin-C levels with mortality in elderly persons with heart failure, stratified by creatinine (Cr) and estimated glomerular filtration rate (eGFR) levels. The figure displays the annual mortality risk for participants with cystatin-C levels above (high) or below (low) the median of 1.26 mg/l. The adjusted hazard ratios (HR) compare high versus low cystatin-C levels among subgroups of participants with high creatinine (above median value of 1.05 mg/dl) or low creatinine (<1.05 mg/dl), as well as by high eGFR (>61 ml/min/1.73 m2) or low eGFR (<61 ml/min/1.73 m2).